TY - JOUR
T1 - Immunity, inflammation, and cancer
T2 - An eternal fight between good and evil
AU - Shalapour, Shabnam
AU - Karin, Michael
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Cancer development and its response to therapy are strongly influenced by innate and adaptive immunity, which either promote or attenuate tumorigenesis and can have opposing effects on therapeutic outcome. Chronic inflammation promotes tumor development, progression, and metastatic dissemination, as well as treatment resistance. However, cancer development and malignant progression are also associated with accumulation of genetic alterations and loss of normal regulatory processes, which cause expression of tumor-specific antigens and tumor-Associated antigens (TAAs) that can activate antitumor immune responses. Although signals that trigger acute inflammatory reactions often stimulate dendritic cell maturation and antigen presentation, chronic inflammation can be immunosuppressive. This antagonism between inflammation and immunity also affects the outcome of cancer treatment and needs to be considered when designing new therapeutic approaches.
AB - Cancer development and its response to therapy are strongly influenced by innate and adaptive immunity, which either promote or attenuate tumorigenesis and can have opposing effects on therapeutic outcome. Chronic inflammation promotes tumor development, progression, and metastatic dissemination, as well as treatment resistance. However, cancer development and malignant progression are also associated with accumulation of genetic alterations and loss of normal regulatory processes, which cause expression of tumor-specific antigens and tumor-Associated antigens (TAAs) that can activate antitumor immune responses. Although signals that trigger acute inflammatory reactions often stimulate dendritic cell maturation and antigen presentation, chronic inflammation can be immunosuppressive. This antagonism between inflammation and immunity also affects the outcome of cancer treatment and needs to be considered when designing new therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=84941660341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941660341&partnerID=8YFLogxK
U2 - 10.1172/JCI80007
DO - 10.1172/JCI80007
M3 - Review article
C2 - 26325032
AN - SCOPUS:84941660341
SN - 0021-9738
VL - 125
SP - 3347
EP - 3355
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 9
ER -